Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies
Methylphenidate (MPH) is the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), a condition that disrupts daily functioning. Research indicates that individuals with ADHD often experience sensory processing impairments, regardless of co-occurring…
Suggested reading